Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of ...
The fighters who forced Bashar al-Assad into exile began the complex task of governing the Syrian capital. New York Times reporters entering the country saw relics of the deposed regime on the ...
Stock futures edged lower Monday morning as investors eye this week’s key inflation report. The Consumer Price Index (CPI) ...
Happy Birthday to Dame Judi Dench, one of the greatest actresses of our time who turns 90 today. A Hollywood and theatre legend, the ...
Netflix France’s boxing drama has been making waves on Netflix around the globe since its debut on November 8th, 2024, with the streamer confirming that the show created by Franck Gastambide and ...